PROK vs. RARE, CRNX, MOR, NAMS, BHC, IMVT, HCM, GMTX, KNSA, and CPRX
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Ultragenyx Pharmaceutical (RARE), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Immunovant (IMVT), HUTCHMED (HCM), Gemini Therapeutics (GMTX), Kiniksa Pharmaceuticals International (KNSA), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
ProKidney vs. Its Competitors
Ultragenyx Pharmaceutical (NASDAQ:RARE) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.
97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Ultragenyx Pharmaceutical had 12 more articles in the media than ProKidney. MarketBeat recorded 16 mentions for Ultragenyx Pharmaceutical and 4 mentions for ProKidney. Ultragenyx Pharmaceutical's average media sentiment score of 1.30 beat ProKidney's score of 0.54 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.
Ultragenyx Pharmaceutical has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500.
Ultragenyx Pharmaceutical presently has a consensus target price of $81.50, suggesting a potential upside of 160.55%. ProKidney has a consensus target price of $6.25, suggesting a potential upside of 171.74%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Ultragenyx Pharmaceutical.
ProKidney has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. ProKidney's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.
ProKidney has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Summary
ProKidney beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
This page (NASDAQ:PROK) was last updated on 9/4/2025 by MarketBeat.com Staff
